The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma
- Disease/Condition
- Pancreatic Cancer
- Drug/Device/Intervention
- Surufatinib combine immune checkpoint inhibitor
- Study type
- Observational
- Intervention type
- drug
- Primary sponsor
- Luo Cong
- Funder
- Zhejiang Cancer Hospital
- Location
- Hangzhou, China
- Phase
- N/A
- Start date
- Jul 01, 2022
- End date
- Apr 01, 2024
- Enrollment
- 72 participants
Median progression-free survival
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive tumor with a poor prognosis,
 despite the emergence of chemotherapies, unmet medical needs and limited treatment options
 still exist for patients with metastatic PDAC (mPDAC). Surufatinib is a small-molecule
 tyrosine kinase inhibitor that targets vascular endothelial growth factor (VEGFR) 1, 2, 3,
 fibroblast growth factor receptor 1 (FGFR1), and colony stimulating factor 1 receptor
 (CSF-1R), and ex vivo experiments have demonstrated its effect on PC models.
 
 A retrospective analysis of patients with PDAC who underwent surufatinib at Zhejiang Cancer
 Hospital (Hangzhou,China) from July 2022 to July 2023.The database was extracted from the
 preoperative demographics, blood markers, and surgical pathology information of patients
 undergoing surufatinib in the investigators' hospital.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06378580
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06378580 through Pure Global AI's free database. This phase not specified trial is sponsored by Luo Cong and is currently Completed. The study focuses on Pancreatic Cancer. Target enrollment is 72 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.